Clinical Trial Update: Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, pharmacokinetics, and efficacy of ABT-SLV187 in adults with advanced Parkinson's disease; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ABT-SLV187

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Advanced Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-03-15